Filtered By:
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 4921 results found since Jan 2013.
Sexual (Risk) Behavior and Risk-Reduction Strategies of Home-Based Male Sex Workers Who Have Sex with Men (MSW-MSM) in The Netherlands: A Qualitative Study
This study aimed to gain an understanding of sexual (risk) behavior, factors influencing sexual (risk) behavior, and applied risk-reduction strategies of home-based MSW-MSM. For this qualitative study, semi-structured individual interviews were conducted with 20 home-based MSW-MSM in the Netherlands. The interviews' recordings were transcribed verbatim and thematically analyzed with Atlas.ti 8. Condom use was reported to be high during anal sex, but low during oral sex and mostly determined by STI risk perception, trust in clients, and sexual pleasure. Many experienced condom failure, while few knew what to do after condom...
Source: Archives of Sexual Behavior - July 7, 2023 Category: Psychiatry & Psychology Authors: Charlotte M M Peters Ymke J Evers Nicole H T M Dukers-Muijrers Christian J P A Hoebe Source Type: research
Recombinant < em > Fowl aviadenovirus E < /em > (FAdV-E) penton base vaccination fails to confer protection against inclusion body hepatitis (IBH) in chickens
Avian Pathol. 2023 Jul 7:1-6. doi: 10.1080/03079457.2023.2226085. Online ahead of print.ABSTRACTInclusion body hepatitis (IBH) is a metabolic disease affecting chickens, associated with different serotypes of fowl adenovirus (FAdV). Experimentally tested vaccines against IBH include several capsid-based subunit vaccines, but not the penton base protein. In the present study, specific pathogen-free chickens were vaccinated with recombinant penton base expressed from each of two different FAdV serotypes (FAdV-7 and FAdV-8b), followed by challenge with a virulent IBH-causing strain. No protection was observed with either vacc...
Source: Avian Pathology - July 7, 2023 Category: Pathology Authors: Carlotta De Luca Anna Schachner Michael Hess Source Type: research
Status of New Vaccine Introduction - Worldwide, 2016-2021
This report describes the status of introductions globally for eight World Health Organization (WHO)-recommended new and underutilized vaccines, comprising 10 individual vaccine antigens. By 2021, among 194 countries worldwide, 33 (17%) provided all of these 10 WHO-recommended antigens as part of their routine immunization schedules; only one low-income country had introduced all of these recommended vaccines. Universal hepatitis B birth dose; human papillomavirus vaccine; rotavirus vaccine; and diphtheria, tetanus, and pertussis-containing vaccine first booster dose have been introduced by 57%, 59%, 60%, and 72% of all co...
Source: MMWR Morb Mortal Wkl... - July 6, 2023 Category: Epidemiology Authors: Gurpreet Kaur Rebecca M Casey Jaymin C Patel Paul Bloem Jenny A Walldorf Terri B Hyde Source Type: research
The current and future burden of hepatitis B in Switzerland: a modelling study
CONCLUSIONS: Thanks to the historical vaccination programmes and the continued rollout of universal 3-dose coverage in the first year of life, Switzerland is expected to exceed the global health sector strategy targets for the reduction of incidence. While overall prevalence is decreasing, the current diagnosis and treatment levels remain below global health sector strategy targets.PMID:37410921 | DOI:10.57187/smw.2023.40086
Source: Swiss Medical Weekly - July 6, 2023 Category: General Medicine Authors: Francesco Negro Beat M üllhaupt David Semela Sarah Blach Philip Bruggmann Andrea De Gottardi Jean-Francois Dufour Montserrat Fraga Antonio Galante Homie Razavi Joana Vieira Barbosa Devin Razavi-Shearer Source Type: research
Status of New Vaccine Introduction - Worldwide, 2016-2021
This report describes the status of introductions globally for eight World Health Organization (WHO)-recommended new and underutilized vaccines, comprising 10 individual vaccine antigens. By 2021, among 194 countries worldwide, 33 (17%) provided all of these 10 WHO-recommended antigens as part of their routine immunization schedules; only one low-income country had introduced all of these recommended vaccines. Universal hepatitis B birth dose; human papillomavirus vaccine; rotavirus vaccine; and diphtheria, tetanus, and pertussis-containing vaccine first booster dose have been introduced by 57%, 59%, 60%, and 72% of all co...
Source: MMWR Morb Mortal Wkl... - July 6, 2023 Category: Epidemiology Authors: Gurpreet Kaur Rebecca M Casey Jaymin C Patel Paul Bloem Jenny A Walldorf Terri B Hyde Source Type: research
The current and future burden of hepatitis B in Switzerland: a modelling study
CONCLUSIONS: Thanks to the historical vaccination programmes and the continued rollout of universal 3-dose coverage in the first year of life, Switzerland is expected to exceed the global health sector strategy targets for the reduction of incidence. While overall prevalence is decreasing, the current diagnosis and treatment levels remain below global health sector strategy targets.PMID:37410921 | DOI:10.57187/smw.2023.40086
Source: Swiss Medical Weekly - July 6, 2023 Category: General Medicine Authors: Francesco Negro Beat M üllhaupt David Semela Sarah Blach Philip Bruggmann Andrea De Gottardi Jean-Francois Dufour Montserrat Fraga Antonio Galante Homie Razavi Joana Vieira Barbosa Devin Razavi-Shearer Source Type: research
Status of New Vaccine Introduction - Worldwide, 2016-2021
This report describes the status of introductions globally for eight World Health Organization (WHO)-recommended new and underutilized vaccines, comprising 10 individual vaccine antigens. By 2021, among 194 countries worldwide, 33 (17%) provided all of these 10 WHO-recommended antigens as part of their routine immunization schedules; only one low-income country had introduced all of these recommended vaccines. Universal hepatitis B birth dose; human papillomavirus vaccine; rotavirus vaccine; and diphtheria, tetanus, and pertussis-containing vaccine first booster dose have been introduced by 57%, 59%, 60%, and 72% of all co...
Source: MMWR Morb Mortal Wkl... - July 6, 2023 Category: Epidemiology Authors: Gurpreet Kaur Rebecca M Casey Jaymin C Patel Paul Bloem Jenny A Walldorf Terri B Hyde Source Type: research
Can persistent infections with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T- lymphotropic virus (HTLV) be eradicated?
AIDS Res Hum Retroviruses. 2023 Jul 6. doi: 10.1089/AID.2022.0116. Online ahead of print.ABSTRACTPersistent viruses (PV) are hard to be eradicated, even using effective medications, and can persist for a long time in humans, sometimes regardless of treatment. Hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T-cell lymphotropic virus (HTLV) infections, the most common in our era, is still a challenge despite the increased knowledge about their biology. Most of them are highly pathogenic, some causing acute disease or, more often, leading to chronic persistent infections, and so...
Source: Cell Research - July 6, 2023 Category: Cytology Authors: Sandy Vieira Teixeira Gabriela Silva Prates Luiz Augusto M Fonseca Jorge Casseb Source Type: research
Status of New Vaccine Introduction - Worldwide, 2016-2021
This report describes the status of introductions globally for eight World Health Organization (WHO)-recommended new and underutilized vaccines, comprising 10 individual vaccine antigens. By 2021, among 194 countries worldwide, 33 (17%) provided all of these 10 WHO-recommended antigens as part of their routine immunization schedules; only one low-income country had introduced all of these recommended vaccines. Universal hepatitis B birth dose; human papillomavirus vaccine; rotavirus vaccine; and diphtheria, tetanus, and pertussis-containing vaccine first booster dose have been introduced by 57%, 59%, 60%, and 72% of all co...
Source: MMWR Morb Mortal Wkl... - July 6, 2023 Category: Epidemiology Authors: Gurpreet Kaur Rebecca M Casey Jaymin C Patel Paul Bloem Jenny A Walldorf Terri B Hyde Source Type: research
